LifeMax Acquires Rights to Orphan Drug for Netherton Syndrome from Novartis

LifeMax Laboratories, Inc. (“LifeMax”) announced on 8/27/18 an exclusive worldwide license from Novartis Pharma AG for the right to develop, manufacture and commercialize BPR277, a clinical stage asset with positive clinical proof of concept for the treatment of Netherton Syndrome.